Verve Therapeutics Inc (NAS:VERV)
$ 5.61 -0.17 (-2.94%) Market Cap: 474.96 Mil Enterprise Value: 6.30 Mil PE Ratio: 0 PB Ratio: 0.93 GF Score: 37/100

Verve Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 12:30AM GMT
Release Date Price: $21.36 (+5.85%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Great. Okay. So I'm Eric Joseph, Senior Biotech Analyst with JPMorgan. Our next presenting company is Verve Therapeutics, and it's my pleasure to welcome Sekar Kathiresan, CEO, to take us through the story. There is a Q&A session after the presentation. There will be mics circulated around the room. And for those tuning in online, feel free to submit a question via the portal and I'll work those in where appropriate. So with that, Sekar, thanks for your time.

Sekar Kathiresan
Verve Therapeutics, Inc. - Co-Founder, CEO & Director

Okay. Good afternoon. Thank you to the JPM team and Eric for the opportunity to present our story today. My name is Sekar Kathiresan. Prior to founding and leading Verve, I spent 20 years as a cardiologist at Mass General Hospital practicing preventive cardiology and a professor at Harvard Medical School, researching the genetic basis of cardiovascular disease.

At Verve, we are looking to transform the care of cardiovascular

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot